vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $52.3M, roughly 1.3× ACME UNITED CORP). ACME UNITED CORP runs the higher net margin — 1.9% vs -49.0%, a 50.9% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 13.8%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ACU vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $70.6M |
| Net Profit | $985.0K | $-34.6M |
| Gross Margin | 39.7% | — |
| Operating Margin | 3.3% | -56.7% |
| Net Margin | 1.9% | -49.0% |
| Revenue YoY | 13.8% | 81958.1% |
| Net Profit YoY | -40.4% | 54.9% |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | — | ||
| Q3 25 | $49.1M | $70.6M | ||
| Q2 25 | $54.0M | — | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $45.9M | — | ||
| Q3 24 | $48.2M | — | ||
| Q2 24 | $55.4M | — |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.9M | $-34.6M | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $4.5M | — |
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | — | ||
| Q3 25 | 39.1% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 40.8% | — |
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | — | ||
| Q3 25 | 6.1% | -56.7% | ||
| Q2 25 | 11.8% | — | ||
| Q1 25 | 5.3% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 11.5% | — |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.9% | -49.0% | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 3.6% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 8.0% | — |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $1.16 | — | ||
| Q1 25 | $0.41 | — | ||
| Q4 24 | $0.43 | — | ||
| Q3 24 | $0.54 | — | ||
| Q2 24 | $1.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $490.9M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | $503.0M |
| Total Assets | $195.2M | $577.1M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | — | ||
| Q3 25 | $5.1M | $490.9M | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $3.4M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $5.7M | — | ||
| Q2 24 | $3.8M | — |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | — | ||
| Q3 25 | $115.8M | $503.0M | ||
| Q2 25 | $113.7M | — | ||
| Q1 25 | $108.3M | — | ||
| Q4 24 | $107.0M | — | ||
| Q3 24 | $106.3M | — | ||
| Q2 24 | $104.0M | — |
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | — | ||
| Q3 25 | $173.0M | $577.1M | ||
| Q2 25 | $170.9M | — | ||
| Q1 25 | $163.0M | — | ||
| Q4 24 | $162.2M | — | ||
| Q3 24 | $165.5M | — | ||
| Q2 24 | $173.5M | — |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | — | ||
| Q3 25 | $7.1M | $-84.6M | ||
| Q2 25 | $6.3M | — | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $6.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | — | ||
| Q3 25 | $301.0K | $-84.7M | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-4.7M | — | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $4.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 0.6% | -120.1% | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | -10.2% | — | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 15.6% | — | ||
| Q2 24 | 8.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 13.8% | 0.2% | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 4.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | — | ||
| Q4 24 | 3.73× | — | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
